Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin Doses Impact on LDL, CPK, and AST
NCT06910098Completed
- Sponsor
- Central Park Medical College
- Start
- Dec 2023
- Primary completion
- Jun 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised trial of rosuvastatin in hypercholesterolemia (3 arms), sponsored by Central Park Medical College. Primary endpoints: Low Density Lipoprotein at 12 weeks, Creatinine Phosphokinase at 12 weeks and 1 more. Started Dec 2023; status: completed.
02
Drugs
rosuvastatin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06910098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06910098.